TICKERNERD
Menu
VTRSVTRSHealthcare · Drug Manufacturers - Specialty & Generic

VTRS Stock Forecast: Viatris, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$17
−1.05% on the day

The 11 Wall Street analysts covering Viatris, Inc. hold a median 12-month price target of $20 — +18.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$19.5B
Ticker Nerd rank
100 / 100
Median analyst target
$20
Analysts covering
11
Revenue$3.8B+4.9% y/y
Operating income$73.7M
Net income−$118.8M
Free cash flow$322.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.7%
1M
+5.5%
YTD
+39.2%
1Y
+77.7%
From 52W high
−4.4%
From 52W low
+84.7%
$9
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VTRS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Viatris, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
100 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Issuance
95
Growth
93
Accruals
91
Momentum
90
Volatility
87
Revisions
81
Quality
69
Size
10

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Quality (69): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VTRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VTRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Oct 25Jan 26Apr 26Jul 26VTRSHigh $23Median $20Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
6 Buy4 Hold1 Sell
Low $13Median $20High $23

The green dot is the last close — the median target sits +18.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Sept 2026Piper SandlerMaintainsNeutral$12 → $13
9 Sept 2026Leerink PartnersInitiatesOutperform$20
8 Sept 2026Argus ResearchMaintainsBuy$15 → $20
19 May 2026BarclaysMaintainsOverweight$17 → $22
19 May 2026BarclaysMaintainsOverweight—
8 May 2026JP MorganMaintainsNeutral—
8 May 2026Truist SecuritiesMaintainsBuy—
24 Mar 2026BarclaysMaintainsOverweight—
28 Jan 2026Piper SandlerMaintainsNeutral—
16 Jan 2026Argus ResearchUpgradeBuy—
9 Dec 2025BarclaysInitiatesOverweight—
15 Oct 2025Truist SecuritiesInitiatesBuy—
6 June 2025Goldman SachsInitiatesNeutral—
7 Mar 2025JefferiesMaintainsBuy—
5 Mar 2025Piper SandlerReiteratesNeutral—
28 Feb 2025B of A SecuritiesMaintainsUnderperform—
28 Feb 2025BarclaysMaintainsUnderweight—
6 Dec 2024Piper SandlerReiteratesNeutral—
8 Nov 2024BarclaysMaintainsUnderweight—
19 July 2024JefferiesReinstatesBuy$15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTRS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VTRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Viatris, Inc. returned +77.7% against +16.3% for the S&P 500, dividends included.

VTRS vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26VTRSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VTRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.7%
Analysts raising
5
Analysts cutting
0
Fundamentals

Viatris, Inc. (VTRS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
235.8×

Cheaper than 3% of US stocks

Price / sales
1.3×

Cheaper than 63% of US stocks

Price / book
1.3×

Cheaper than 61% of US stocks

EV / EBITDA
7.4×

Cheaper than 48% of US stocks

Growth & margins
Revenue growth (YoY)
4.9%

Higher than 39% of US stocks

Earnings growth (YoY)
4.9%

Higher than 42% of US stocks

Gross margin
38.8%

Higher than 48% of US stocks

Operating margin
12.6%

Higher than 68% of US stocks

Net margin
−2.8%

Higher than 27% of US stocks

Returns & dividend
Return on equity
−2.8%

Higher than 41% of US stocks

Return on assets
2.7%

Higher than 63% of US stocks

Dividend yield
2.8%

Higher than 60% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Viatris, Inc. (VTRS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Viatris, Inc. has a market value of $19.5B and an enterprise value of $31.6B.

  • Revenue in the twelve months to 30 June 2026: $14.7B. The latest quarter grew 4.9% year on year.

  • Net income over the same four quarters: −$410.7M, a −2.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.36.

  • Free cash flow in the twelve months to 30 June 2026: $1.8B, after $376.0M of capital spending.

  • Viatris, Inc. spent $300.1M on share buybacks and $557.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.2B.

  • Trailing P/E: 235.8×; forward P/E: 6.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.84%, paying out 960% of earnings.

  • Viatris, Inc. employs 30,000 people — $491K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

VTRS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
VTRSViatris, Inc.$19.5B
100
UTHRUnited Therapeutics Corp.$21.0B
81
NBIXNeurocrine Biosciences, Inc.$14.6B
88
ZTSZoetis, Inc.$29.5B
43
ELANElanco Animal Health, Inc.$11.2B
98
ALKSAlkermes Plc$7.2B
61
HIMSHims & Hers Health, Inc.$6.5B
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Viatris, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VTRS news & analysis

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

PRNewsWire · 16 Sept 2026positive

Viatris announced that Japan's Ministry of Health, Labour and Welfare has approved WAKIX (pitolisant) for treating excessive daytime sleepiness associated with obstructive sleep apnea syndrome and for narcolepsy (types 1 and 2, with and without cataplexy). This first-in-class treatment addresses a high unmet medical need and advances Viatris' innovative portfolio in Japan.

Why it matters — Approval of a first-in-class product in Japan expands Viatris' innovative portfolio in a key market and opens a new commercial opportunity for the company.

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

Seeking Alpha · 9 Sept 2026positive

Viatris reported stronger Q2 earnings quality, with adjusted net income and EPS up 11% and free cash flow doubling year-over-year. Deleveraging is on track, while buybacks, dividends, pipeline progress, and new-product approvals add to the expansion story beyond its mature portfolio.

Why it matters — The report signals that Viatris' improved cash generation is already supporting shareholder returns while pipeline milestones offer additional growth optionality beyond its mature portfolio.

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · 9 Sept 2026positive

Zacks Research highlights Viatris (VTRS) as a top-ranked value stock based on its proprietary Style Scores system, which is designed to help investors identify strong, market-beating stocks. The article discusses how investors can use these style scores when selecting stocks for their portfolios.

Why it matters — A VTRS watcher would care because the stock receiving top value-stock rankings from Zacks could raise its visibility and attract investor attention.

17 Ideal 'Safer' Buyable August Dogs Dug Up After 10 Years

Seeking Alpha · 28 Aug 2026neutral

An analysis of 89 top ten-year collected dividend dogs focuses on yield-based strategies and safety via free cash flow coverage, identifying 17 "safer" dogs projected to deliver average net gains of 39.61% by August 2027 with risk profiles generally below market volatility. These safer dogs meet the ideal of annual dividends from a $1,000 investment exceeding share price, signaling strong income potential.

Why it matters — Viatris watchers would care because the screening methodology evaluates dividend income and free cash flow coverage, criteria that bear on how VTRS may be positioned among safer income-generating stocks.

Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

Proactive Investors · 28 Aug 2026negative

Cavendish reiterated its 'buy' rating on Shield Therapeutics after the company reached an agreement to take full commercial control of its main US product from Viatris, keeping its target price at 23 pence.

Why it matters — For Viatris watchers, this reflects the company surrendering commercial control of Shield's primary US product, a change in its commercial responsibilities and product portfolio.

FAQ

Frequently asked questions about VTRS stock

What is the VTRS stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Viatris, Inc. have a median 12-month price target of $20, with estimates ranging from $13 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VTRS stock a buy right now?

Of the 11 analysts covering Viatris, Inc., 6 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Viatris, Inc. 100 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VTRS?

As at 19 Sept 2026, Viatris, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will VTRS stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +18.0% from the last close, and Ticker Nerd's factor model ranks Viatris, Inc. 100 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VTRS stock forecast for 2030?

No analyst covering Viatris, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $23 over the next 12 months.

How has VTRS stock performed over the past year?

Viatris, Inc. returned +77.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viatris, Inc. do?

Viatris Inc. is a global healthcare company focused on expanding access to a broad range of medicines across multiple therapeutic areas.

What is the latest news on VTRS?

The most recent item we track (PRNewsWire, 16 Sept 2026): "Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome". Viatris announced that Japan's Ministry of Health, Labour and Welfare has approved WAKIX (pitolisant) for treating excessive daytime sleepiness associated with obstructive sleep apnea syndrome and for narcolepsy (types 1 and 2, with and without cataplexy). This first-in-class treatment addresses a high unmet medical need and advances Viatris' innovative portfolio in Japan.

Company

About Viatris, Inc.

Viatris Inc. is a global healthcare company focused on expanding access to a broad range of medicines across multiple therapeutic areas. Its portfolio includes established prescription brands, generic and complex generic medicines, biosimilars, and over-the-counter consumer products that support treatment and disease management worldwide. Viatris serves patients and healthcare systems in developed and emerging markets through operations organized across Developed Markets, Greater China, JANZ, and Emerging Markets. The company also emphasizes reliable manufacturing, distribution, and supply continuity for essential therapies, helping connect more people to trusted medicines regardless of geography or circumstance. Headquartered in Canonsburg, Pennsylvania, Viatris operates as a diversified pharmaceutical business with a broad international footprint and a focus on scalable healthcare access.

CEO Mr. Scott Andrew Smith Ph.D. · 30,000 employees · United States · https://www.viatris.com